Skip to main content
The World Allergy Organization Journal logoLink to The World Allergy Organization Journal
. 2022 Feb 1;15(1):100609. doi: 10.1016/j.waojou.2021.100609

World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) Guidelines update – I – Plan and definitions

Alessandro Fiocchi a,, Antonio Bognanni b, Jan Brożek c, Motohiro Ebisawa d, Holger Schünemann b,e; the WAO DRACMA guideline group
PMCID: PMC8818560  PMID: 35145603

Abstract

Since the World Allergy Organization (WAO) Diagnosis and Rationale against Cow's Milk Allergy (DRACMA) Guidelines were published 10 years ago, new evidence has accumulated about the diagnosis, therapy, and specific immunotherapy for cow's milk allergy (CMA). For this reason, WAO has felt the need to update the guidelines.

We introduce here this update. The new DRACMA guidelines aim to comprehensively address the guidance on diagnosis and therapy of both IgE non-IgE-mediated forms of cow's milk allergy in children and adults. They will be divided into 18 chapters, each of which will be dedicated to an aspect. The focus will be on the meta-analyzes and recommendations that will be expressed for the 3 most relevant clinical aspects: (a) the diagnostic identification of the condition; (b) the choice of the replacement formula in case of CMA in infancy when the mother is not able to breastfeed, and (c) the use of specific immunotherapy for cow's milk protein allergy.

Keywords: Food allergy, Cow's milk allergy, Oral immunotherapy, GRADE

Introduction

IgE-mediated cow's milk protein allergy (IgE-CMA) has been a primary topic of interest for WAO since 2010, the year in which the first Grading of Recommendations Assessment, Development, and Evaluation (GRADE)-based guidelines on the management of this condition were published.1 Of notice, the World Allergy Organization (WAO) Diagnosis and Rationale against Cow's Milk Allergy (DRACMA) Guidelines had a noticeable impact on clinical practice regarding IgE-CMA, raising awareness on several aspects.2

First, the DRACMA guidelines presented a more nuanced and comprehensive diagnostic process, which, despite being generally based on oral food challenges (OFCs), could be supplemented, and in some cases replaced by an appropriate use of other tests such as skin prick test (SPT) and specific IgE determination (sIgE). The decision of which approach should be employed required an high-degree of personal contextualization, both depending on the specific circumstances and the values and preferences of the clinicians/patients.

Second, the guidelines pointed out the necessity by infants aged <2 years of a substitutive formula whenever their mother could not breastfeed, with the best choice being frequently cow's milk extensively Hydrolyzed Formula (eHF). Where available, Hydrolyzed Rice Formula (HRF) was considered equivalent, while Amino Acid Formulae (AAF) was to be reserved for the most severe cases. Soy formulae were generally deemed not to be a first choice, while milk from other mammals (eg, donkey, camel, mare, sheep, and ewe) was not to be used given the mismatch with the infants’ nutritional needs. Also in this case, the choice should rely on the context, and the values and preferences of the clinicians/patients.

Third, Oral Immunotherapy (OIT) with milk was considered as an experimental procedure, not suitable for routine clinical practice.3

Ten years later, despite the DRACMA methods still being valid,4 the scenario has dramatically evolved, prompting an update in guidance. Differently from other food allergies, reported by many as increasingly prevalent, CMA appears to have not undergone this trajectory.5,6 Even so, milk allergy remains a priority concern for allergists and pediatrician worldwide, with dairy anaphylaxis being now more common than peanut anaphylaxis, and the most frequently associated to lethal allergic reactions, as shown in a recent review on school-aged children with CMA.7

Image 1

We introduce herein the updated DRACMA guidelines. We aim to illustrate the progress in diagnosis, therapy, and immunotherapy of IgE-CMA that could tailor the management of CMA. We will shortly indicate the guidelines published after DRACMA, over the decade 2010/2020. Finally, we will present the structure of the reviewed guidelines that took place between 2016 and 2021 and whose publication begins with this issue of the World Allergy Organization Journal. The new DRACMA guidelines aim to comprehensively address the guidance on diagnosis and therapy of both IgE non-IgE-mediated forms of CMA.

2010–2020: Open questions in diagnosis, therapy, and immunotherapy of CMA

The diagnosis was preached by the DRACMA guidelines on the use of the OFC as a "gold standard" for IgE-CMA. This somewhat bombastic definition emphasize the need of a scientifically correct diagnosis, in order to prevent CMA overdiagnosis. The OFC certainly retains its validity, but over the years, its limitations have become increasingly evident. For example, OFC results are not predictive of the severity of subsequent reactions.8 Also, there is no direct correlation between the eliciting threshold experienced by children during an OFC and the reaction's severity upon accidental exposure.9 Tools such as the Basophil Activation Test (BAT) have been developed to minimize the risk of severe reactions to the OFC,10,11 being also proposed as replacement tests of the OFC.12 In addition, serious reactions to the OFC have been described, up to a case of fatal reaction.13 These considerations will affect the direction of recommendations formulated by the guideline panel for the diagnosis of IgE mediated allergy. Other challenges inherent the diagnosis of IgE-CMA are the reassessment of the role of total and specific IgE assay, the interpretation of skin tests, and the possible role of molecular testing in diagnostic evaluation.14,15

Finally, as about 70% of IgE-CMA patients are found to tolerate baked milk, the latter might be considered for a role in the CMA diagnostic pathway, prior to fresh milk testing16

The elimination diet for milk, which prepares the OFC in IgE-mediated food allergy, completely replaces it in most guidelines for the diagnosis of non IgE-mediated CMA (non-IgE-CMA).17 We will see later how this might have profound influence over the epidemiologic estimates of the disease, which will be among the priority topics to be addressed in the new DRACMA guidelines. Specifically, we will try to address in an evidence-based manner the following questions: Should an elimination diet be followed by OFC in the individuals suspected of non-IgE-mediated CMA? Is there any use of atopy patch test to milk in these children? Is there any role for endoscopy ± biopsy in children with suspected milk-induced Eosinophilic Esophagitis (EoE) or non-esophageal Eosinophilic Gastrointestinal Disorders (EGIDs), including eosinophilic gastroenteritis and colitis? Are the diagnostic challenge procedures, recommended by specific guidelines for Food-Protein-Induced Enterocolitis Syndrome (FPIES),18 adequately informed by evidence?

Image 2

In synthesis, reconciling the diagnostic procedures for the different forms of CMA will be a challenge for the new DRACMA guidelines.19

A peculiar issue to consider, in the treatment of CMA, given the pivotal importance of maternal milk for children up to 24/36 months of age, is to confirm the evidence underlying the suggestion of cow's milk (CM) elimination diet for mothers breastfeeding allergic infants.20 In the past 10 years, the involvement of formulas in the management of CMA has been profoundly expanded, with extensively hydrolyzed formulas (eHFs),21 rice hydrolyzed formula (HRF),22 amino acid formulae (AAF),23 camel and dromedary milk,24 and donkey milk25 receiving increasing attention from the health community and being implemented in medical practice. To properly represent the change of the topic, we will update the systematic review investigating the effect of formulas in the management of CMA.

Another important aspect to account for is the reported effect of associating probiotics with formulas, either administered separately or mixed in the same formulation, on the duration of IgE-CMA.26,27 Another issue that will be investigated is the employment of new synbiotic-supplemented amino acid-based formulas.28,29

Over the course of the last decade, several advances have been done in developing novel protocols of CM oral immunotherapy, with the most notable examples being the weekly30 or slow up-dosing regimens,31 the rapid oral desensitization combined with omalizumab,32 different maintenance feeding regimens,33 and baked milk oral immunotherapy34, 35, 36

Previous systematic reviews investigating this aspect of IgE-CMA management were published in 2012 and 2017 including, but not limited to, OIT for IgE-CMA.37,38 The systematic review and guideline publication focusing on this topic will be the first among the 2021 DRACMA-related publications.

CMA guidelines published after DRACMA

Since the first edition of DRACMA, other guidelines, consensuses, and position papers have been issued on CMA at the regional or national level. Some of them were national guidance items, implementing locally the DRACMA guidelines, others were de novo publications, developed using different methodologies. We report in Table 1 a list of the main CMA guidelines published over the course of the past 10 years.

Table 1.

Main consensus, position papers, and guidelines produced worldwide between 2010 and 2020

Country/region Issuing scientific society Guideline identification DRACMA based? Main characteristics Ref.
Europe ESPGHAN ESPGHAN CMPA guidelines No Focus on non-IgE CMA 39
Europe European Academy of Allergy and Clinical Immunology (EAACI) EAACI food allergy guidelines No Not limited to CMA 40
France Société Française de Pédiatrie Dietetic treatment of cow's milk protein allergy. No Limited to treatment 41
Italy Emilian Working Group on Pediatric Allergy and Gastroenterology A practical guide No Focus on diagnosis and management in primary care 42
Italy Italian Society of Pediatric Allergy DRACMA Yes Italian translation 43
United Kingdom National Institute for Health and Care Excellence (NICE) MAP (Milk Allergy in Primary Care) No Focus on non IgE-CMA in primary care 44
United Kingdom NICE-derived i-MAP (international MAP) Partly Focus on non IgE CMA in primary care 45
United Kingdom British Society for Allergy and Clinical Immunology (BSACI) BSACI cow's milk allergy guideline No Comprehensive 46
United Kingdom NICE-derived Updated i-MAP (international MAP) Partly Focus on CMA in primary care 47
Finland Finnish Allergy Programme
2008–2018
Practical recommendations of the Finnish Allergy Programme 2008–2018 for prevention, diagnosis, and treatment No CMA as part of food allergy management in children 48
Spain Spanish Society of Pediatric Clinical Immunology and Allergology (SEICAP) Spanish CM guideline Partly Comprehensive 49
Spain Spanish Society of Paediatric Gastroenterology, Hepatology, and Nutrition (SEGHNP), Spanish Association of Paediatric Primary Care (AEPAP), Spanish Society of Extra-hospital Paediatrics and Primary Health Care (SEPEAP), and the Spanish Society of Paediatric ClinicaL Immunology, Allergy, and Asthma (SEICAP) Spanish CM guideline for non IgE-mediated CMA No Focus on non IgE CMA 50
Turkey Turkish Society of Pediatrics Turkish Consensus Partly Focus on primary care 51
Middle East Independent group Middle East consensus Yes Focus on primary care 52
India Indian Society of Pediatric Gastroenterology, Hepatology and Nutrition Indian Consensus No Focus on primary care 17
China World Allergy Organization (WAO) DRACMA Yes Mandarin translation 53
China Independent group Intensive DRACMA reading Yes Implementation in China 54
Japan Japanese Society of Pediatric Allergy and Clinical Immunology (JSPACI); Japanese Society of Allergology (JSA) Japanese guidelines Partly Not limited to CMA 55
Mexico Independent group GL-APLV Partly Comprehensive 56
South America World Allergy Organization (WAO) DRACMA Yes Spanish translation 57

Among the publications above, the one most implemented is the UK NICE – derived guideline, the iMAP guideline. It includes an algorithm for the diagnostic and therapeutic approaches, based on the heterogeneous clinical manifestations of CMA (both non-IgE and IgE).45 Interestingly, the diagnostic process for CMA accounts for a diagnosis not confirmed through OFC, given that a series of conditions are met (improvement on a strict cow's milk protein-free elimination diet for at least 2 weeks; clinical relapse on subsequent cow's milk open challenge), possibly leading to an overestimation of non-IgE-CMA. After their implementation in Northern Ireland, the use of hypoallergenic formulas largely increased, exceeding the expected epidemiological figures58,59

The quality of guidelines on CMA, published between 2010 and 2015, was assessed through the Appraisal of Guidelines for Research and Evaluation (AGREE II) tool.60 The appraisal highlighted the lack of a defined quality standard, as only 3 presented satisfactory scores across the key domains. In light of this, in the present update of the DRACMA guidelines we strive to adhere to the highest methodological standards in the evaluation of evidence and its translation into recommendations.

Methods applied in the 2021 DRACMA guidelines

We followed the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach {PMID: 21195583} and the European Commission methods for developing practice guidelines.61 WAO established a multidisciplinary guideline panel (DRACMA Scientific Committee) composed of content experts and representatives of key stakeholders, including patient representatives, nutritionists, and general practitioners. All panel members declared their actual, potential, and/or perceived competing interests. Those were reviewed by an anonymous WAO committee that decided which panel members should abstain from voting on selected recommendations related to immunotherapy, formulas, and diagnosis of CMA.

A group of methodology experts from the McMaster GRADE Centre performed systematic reviews of the evidence and led the process of developing recommendations.

The DRACMA guideline panel generated a set of 61 questions and determined their priority to be answered with recommendations (Supplementary material). The methodology group performed necessary systematic reviews and prepared GRADE summary of findings tables. The voting panel members followed the evidence-to-decision (EtD) framework to develop recommendations either by in-person or online discussion following the modified Delphi approach. We published all decisions and the rationale for the recommendations as appendices to the guidelines.

General structure of the 2021 DRACMA guidelines

The original guideline comprised 19 chapters merged into a single publication. This time we decided to publish the chapters separately in a dedicated series in the World Allergy Organization Journal to facilitate the dissemination and the implementation of the guideline. For this reason the chapters have been separated, and every topic will be published in a single article.

Table 2 shows the publication plan. Due to peer review process, the articles will not necessarily be published in the order indicated. We will start with the guidelines on OIT, those for which a greater harvest of new data has been produced. The guideline is submitted together with the metanalysis supporting it. Other articles will be published regularly, so that the project will configure a Summa of the relevant information about CMA.

Table 2.

Plan of the DRACMA publications

Topic Method of preparation
General
1. Overview and definitions This paper
2. CMA epidemiology and natural history Narrative review
3. CM allergens and immunologic mechanisms Narrative review
4. Clinical presentations: IgE-mediated Narrative review
5. Clinical presentations: non IgE-mediated Narrative review
6. Comparison among different guidelines Systematic review
7. DRACMA methodology Synthesis of methods
CMA diagnosis
8. Diagnosis of CMA Systematic review
9. Recommendations on CMA diagnosis Guideline
Treatment options
10. Breastfeeding a baby with CMA Narrative review
11. Substitutive formulae Systematic review
12. Recommendations on substitutive treatment Guideline
13. Oral Immunotherapy for CMA Systematic review
14. Recommendations on CMA OIT Guideline
15. Other milks (goat's, ewe's, mare's, donkey's, camel's, and substitutes from non-animal sources) Narrative review
16. Nutritional considerations in CMA infants Narrative review
Conclusions
17. Which is the 1st choice formula case by case? Synthesis of recommendations
18. Unmet needs. Recommendations for research. Recommendation for the implementation of the DRACMA guidelines. Periodical update of DRACMA. Synthesis of recommendations

Glossary of CMA

In developing the metanalyses and the guidelines, we adhered to the following definitions:

  • -

    Cow's milk hypersensitivity indicates non-allergic hypersensitivity (traditionally termed “cow's milk intolerance”) and allergic milk hypersensitivity

  • -

    Cow's milk allergy (CMA) indicates “a hypersensitivity reaction initiated by specific immunological mechanisms62

  • -

    IgE-mediated CMA (IgE-CMA) indicates a hypersensitivity reaction to cow's milk proteins initiated by specific Immunoglobulin E binding to Fcε receptors on effector cells as mast cells and basophils. This causes release of histamine and other preformed mediators, and rapid symptom onset.63

  • -

    Non IgE-mediated CMA (non-IgE-CMA) indicates a hypersensitivity reaction to cow's milk proteins initiated by non-IgE mediated (mainly cell-mediated) mechanisms. Non-IgE-mediated milk reactions are typically delayed in onset

  • -

    Anaphylaxis is defined according to the amended WAO criteria for the diagnosis of anaphylaxis.64

Many other definitions of clinical presentations and pathologic mechanisms have been adopted during the development of the guidelines. When necessary, they will be specified in the respective papers.

What is next

One of the determinants of the profound heterogeneity in the management of CMA consists in the wide spectrum of professional figures (paediatrician, allergists, gastroenterologists, and so forth) dealing with it. Another is the contradictory guidance provided by a large number of guidelines and position papers. As a consequence, the 2021 updated DRACMA guidelines aim to comprehensively address the diagnostic and therapeutic fields of CMA, harmonizing the collaboration between the various specialist figures.

By their very nature, guidelines make clarity. Clarity is bound to reduce both underdiagnosis and especially overdiagnosis of CMA. We hope we have done the allergy community a good service, and we apologize right now if something went wrong.

Mario Sánchez-Borges

Before proceeding with the publication of the guidelines, we want to celebrate the remarkable life and academic accomplishments of one of our fellow authors. Mario Sánchez-Borges, MD, was a true leader for the entire international allergy community, without whose guidance and contribution, the realization of these guidelines would not have been possible. As a previous WAO president (2016–2017) and Councilor, Mario has been an impulse and prime mover of DRACMA. He participated in the drafting of all the parts that will report him as author. His kindness and generosity will stay unperished, living through the numerous and joyful memories he left in so many of us.

Image 3

Consent to publish

All authors agree to the publication of this manuscript in World Allergy Organization Journal.

Ethics statement

This manuscript is an editorial. It did not involve human subjects.

Author contributions

AF initiated the concept and contributed made the first draft. AB, JB, ME, and HS participated in the development of the document. All authors reviewed and approved the final manuscript.

Funding

This document was supported by the World Allergy Organization.

Declaration of competing interest

S Arasi, S Bahna, Bognanni, J Brożek, D Chu, L Dahdah, E Galli, R Kamenwa, H Li, A Martelli, R Pawankar, H Schünemann, R Targino, L Terracciano, and A Warner have no conflicts to disclose. Relationships reported related to the submitted work: IJ Anstotegui – Abbott, Amgen, Astra Zeneca, Bayer, Bial, Faes Farma, Hikma, Menarini, Merck, Mundipharma, Roxall, Sanofi, Stallergenes, UCB. A Assa’ad – Aimmune Therapeutics, DBV Technologies, Astella, ABBVIE, Novartis, Sanofi, FARE, NIH and an intellectual property patent licensed to Hoth. R Berni Canani – Ch.Hansen, Danone, DVB, Humana, iHealth, Kraft Heinz, Mead Johnson, Nestlè, Novalac, Nutricia, Sanofi. M Bozzola – Danone C Dupont – Nestle Health Science, Nestle France, Nutricia, Novalac, Sodilac, Abbott, Danone, and stock ownership at DBV Technologies. M Ebisawa – DBV Technologies, Mylan, ARS Pharmaceuticals, Novartis. A Fiocchi – Abbott, Danone. G Lack – FARE, National Peanut Board (NPB), The Davis Foundation, Action Medical Research, UK Food Standards Agency, Medical Research Council, DBV Technologies, Mission Mighty Me, Novartis, Sanofi-Genyzme, Regeneron, ALK-Abello, Lurie Children's Hospital. A Nowak-Wegrzyn – Nestle, Nutricia, Novartis, Gerber, Aimmune. N Papadopoulos – Novartis, Nutricia, HAL Allergy, Menarini/Faes Farma, Sanofi, Mylan/Meda, Biomay, AstraZeneca, GSK, MSD, ASIT Biotech, Boehringer Ingelheim, Gerolymatos International SA, Capricare. M Said – Nestle, Nutricia, Abbott, Bayer for Anaphylaxis Australia. J Spergel – DBV Technologies, Regeneron, Sanofi, and Aimmune. H Szajewska – Ausnutria, Cargill, Danone, Else Nutrition, Hipp, Nestle, and Nestle Nutrition Institute. Y Vandenplas – Abbott Nutrition, Biogaia, Biocodex, By Heart, CHR Hansen, Danone, ELSE Nutrition, Friesland Campina, Hero, Hypocrata, Nestle Health Science, Nestle Nutrition Institute, Nutricia, Mead Johnson Nutrition, Orafti, Phacobel, Phathom Pharmaceuticals, Sari Husada, United Pharmaceuticals (Novalac), Wyeth, Yakult. C Venter – Reckitt Benckiser, Nestle Nutrition Institute, Danone, Abbott Nutrition, Else Nutrition, and Before Brands, DBV Technologies. S Waserman – Novartis-basic science work on peanut allergy, Aimmune-peanut OIT trial, Medical Advisor to Food Allergy Canada, and Pfizer, Bausch, Kaleo-consultant for epinephrine autoinjectors. GWK Wong – Nestle, Danone.

Acknowledgement

Mario Sánchez Borges, MD, of Caracas, Venezuela, and a Past President of the World Allergy Organization (2016–2017), was a major contributor to the development of the guidelines until his death in early 2021. His contributions to the field are immense. He will be greatly missed both professionally and personally.

Footnotes

Appendix A

Supplementary data to this article can be found online at https://doi.org/10.1016/j.waojou.2021.100609.

Contributor Information

Alessandro Fiocchi, Email: alessandro.fiocchi@allegriallergia.net.

the WAO DRACMA guideline group:

Ignacio J. Ansotegui, Stefania Arasi, Amal H. Assa'ad, Sami L. Bahna, Roberto Berni Canani, Martin Bozzola, Derek Chu, Lamia Dahdah, Christophe Dupont, Ramon Targino Firmino, Elena Galli, Rose Kamenwa, Gideon Lack, Haiqi Li, Alberto Martelli, Anna Nowak-Węgrzyn, Nikolas G. Papadopoulos, Ruby Pawankar, Maria Said, Mario Sánchez-Borges, Raanan Shamir, Jonathan M. Spergel, Hania Szajewska, Luigi Terracciano, Yvan Vandenplas, Carina Venter, Amena Warner, Susan Waserman, and Gary W.K. Wong

Appendix A. Supplementary data

The following is the supplementary data to this article:

Multimedia component 1
mmc1.docx (20.8KB, docx)

References

  • 1.Fiocchi A., Brozek J., Schünemann H., et al. World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) Guidelines. World Allergy Organ J. 2010;3:57–161. doi: 10.1097/WOX.0b013e3181defeb9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Dahdah L., Arasi S., Valluzzi R.L., Fierro V., Fiocchi A. How guideline can shape clinical practice globally: the diagnosis and rationale for action against cow's milk allergy experience. Curr Opin Allergy Clin Immunol. 2019;19:185–191. doi: 10.1097/ACI.0000000000000513. [DOI] [PubMed] [Google Scholar]
  • 3.Brożek J.L., Terracciano L., Hsu J., et al. Oral immunotherapy for IgE-mediated cow's milk allergy: a systematic review and meta-analysis. Clin Exp Allergy. 2012;42:363–374. doi: 10.1111/j.1365-2222.2011.03948.x. [DOI] [PubMed] [Google Scholar]
  • 4.Ruszczyński M., Horvath A., Dziechciarz P., Szajewska H. Cow's milk allergy guidelines: a quality appraisal with the AGREE II instrument. Clin Exp Allergy. 2016;46:1236–1241. doi: 10.1111/cea.12784. [DOI] [PubMed] [Google Scholar]
  • 5.Sicherer S.H., Sampson H.A. Food allergy: a review and update on epidemiology, pathogenesis, diagnosis, prevention, and management. J Allergy Clin Immunol. 2018;141:41–58. doi: 10.1016/j.jaci.2017.11.003. [DOI] [PubMed] [Google Scholar]
  • 6.Flom J.D., Sicherer S.H. Epidemiology of cow's milk allergy. Nutrients. 2019;11:1051. doi: 10.3390/nu11051051. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Baseggio Conrado A., Patel N., Turner P.J. Global patterns in anaphylaxis due to specific foods: a systematic review. J Allergy Clin Immunol. 2021 doi: 10.1016/j.jaci.2021.03.048. Epub ahead of print. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Pettersson M.E. Prediction of the severity of allergic reactions to foods. Allergy. 2018;73:1532–1540. doi: 10.1111/all.13423. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Eigenmann P.A., Ebisawa M., Greenhawt M., et al. Addressing risk management difficulties in children with food allergies. Pediatr Allergy Immunol. 2021;32:658–666. doi: 10.1111/pai.13455. [DOI] [PubMed] [Google Scholar]
  • 10.Santos A.F., Du Toit G., O'Rourke C., et al. Biomarkers of severity and threshold of allergic reactions during oral peanut challenges. J Allergy Clin Immunol. 2020;146:344–355. doi: 10.1016/j.jaci.2020.03.035. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Kawahara T. Risk prediction of severe reaction to oral challenge test of cow's milk. Eur J Pediatr. 2019;178:181–188. doi: 10.1007/s00431-018-3274-z. [DOI] [PubMed] [Google Scholar]
  • 12.Santos A.F., Brough H.A. Making the most of in vitro tests to diagnose food allergy. J Allergy Clin Immunol Pract. 2017;5:237–248. doi: 10.1016/j.jaip.2016.12.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Statement by the American College of Allergy, Asthma & Immunology, American Academy of Allergy, Asthma & Immunology, and the Canadian Society of Allergy and Clinical Immunology . 2017. Allergists respond to death of 3 year-old boy during oral food challenge.https://acaai.org/allergists-respond-death-3-year-old-boy-during-oral-food-challenge Available from: [Google Scholar]
  • 14.Fiocchi A., Nowak-Węgrzyn A. The fascinating world of molecular diagnosis in the management of food allergy: nondum matura est. Curr Opin Allergy Clin Immunol. 2011;11:200–203. doi: 10.1097/ACI.0b013e32834694ae. [DOI] [PubMed] [Google Scholar]
  • 15.Foong R.X., Dantzer J.A., Wood R.A., Santos A.F. Improving diagnostic accuracy in food allergy. J Allergy Clin Immunol Pract. 2021;9:71–80. doi: 10.1016/j.jaip.2020.09.037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Kim J.S. Dietary baked milk accelerates the resolution of cow's milk allergy in children. J Allergy Clin Immunol. 2011;128(1):125–131. doi: 10.1016/j.jaci.2011.04.036. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Matthai J., Sathiasekharan M., Poddar U., et al. Indian Society of Pediatric Gastroenterology, Hepatology and Nutrition; Pediatric Gastroenterology Chapter of Indian Academy of Pediatrics. Guidelines on Diagnosis and Management of Cow's Milk Protein Allergy. Indian Pediatr. 2020;57:723–729. [PubMed] [Google Scholar]
  • 18.Nowak-Wegrzyn A., Chehade M., Groetch M.E., et al. International consensus guidelines for the diagnosis and management of food protein-induced enterocolitis syndrome: executive summary-workgroup report of the adverse reactions to foods committee, American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2017;139:1111–1126. doi: 10.1016/j.jaci.2016.12.966. [DOI] [PubMed] [Google Scholar]
  • 19.Dahdah L., Fierro V., Mennini M., Arasi S., Fiocchi A. What's next for DRACMA? Expert Rev Clin Immunol. 2018;14:649–651. doi: 10.1080/1744666X.2018.1500900. [DOI] [PubMed] [Google Scholar]
  • 20.Munblit D., Perkin M.R., Palmer D.J., Allen K.J., Boyle R.J. Assessment of evidence about common infant symptoms and cow's milk allergy. JAMA Pediatr. 2020 Jun 1;174(6):599–608. doi: 10.1001/jamapediatrics.2020.0153. [DOI] [PubMed] [Google Scholar]
  • 21.Stróżyk A., Horvath A., Meyer R., Szajewska H. Efficacy and safety of hydrolyzed formulas for cow's milk allergy management: a systematic review of randomized controlled trials. Clin Exp Allergy. 2020;50:766–779. doi: 10.1111/cea.13669. [DOI] [PubMed] [Google Scholar]
  • 22.Vandenplas Y., De Greef E., Hauser B., Paradice Study Group Safety and tolerance of a new extensively hydrolyzed rice protein-based formula in the management of infants with cow's milk protein allergy. Eur J Pediatr. 2014;173:1209–1216. doi: 10.1007/s00431-014-2308-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Fierro V., Valluzzi R.L., Banzato C., et al. A well-tolerated new amino acid-based formula for cow's milk allergy. Immun Inflamm Dis. 2020;8:140–149. doi: 10.1002/iid3.286. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Maryniak N.Z., Hansen E.B., Ballegaard A.R., Sancho A.I., Bøgh K.L. Comparison of the Allergenicity and Immunogenicity of Camel and Cow's Milk-A Study in Brown Norway Rats. Nutrients. 2018;10:1903. doi: 10.3390/nu10121903. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Sarti L., Martini M., Brajon G., et al. Donkey's Milk in the Management of Children with Cow's Milk protein allergy: nutritional and hygienic aspects. Ital J Pediatr. 2019;45:102. doi: 10.1186/s13052-019-0700-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Berni Canani R., Di Costanzo M., Bedogni G., et al. Extensively hydrolyzed casein formula containing Lactobacillus rhamnosus GG reduces the occurrence of other allergic manifestations in children with cow's milk allergy: 3-year randomized controlled trial. J Allergy Clin Immunol. 2017;139:1906–1913. doi: 10.1016/j.jaci.2016.10.050. [DOI] [PubMed] [Google Scholar]
  • 27.Scalabrin D., Harris C., Johnston W.H., Berseth C.L. Long-term safety assessment in children who received hydrolyzed protein formulas with Lactobacillus rhamnosus GG: a 5-year follow-up. Eur J Pediatr. 2017;176:217–224. doi: 10.1007/s00431-016-2825-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Candy D.C.A., Van Ampting M.T.J., Oude Nijhuis M.M., et al. A synbiotic-containing amino-acid-based formula improves gut microbiota in non-IgE-mediated allergic infants. Pediatr Res. 2018;83:677–686. doi: 10.1038/pr.2017.270. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Fox A.T., Wopereis H., Van Ampting M.T.J., et al. ASSIGN study group A specific synbiotic-containing amino acid-based formula in dietary management of cow's milk allergy: a randomized controlled trial. Clin Transl Allergy. 2019;9:5. doi: 10.1186/s13601-019-0241-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Pajno G.B., Caminiti L., Ruggeri P., et al. Oral immunotherapy for cow's milk allergy with a weekly up-dosing regimen: a randomized single-blind controlled study. Ann Allergy Asthma Immunol. 2010;105:376–381. doi: 10.1016/j.anai.2010.03.015. [DOI] [PubMed] [Google Scholar]
  • 31.Kaneko H., Teramoto T., Kondo M., et al. Efficacy of the slow dose-up method for specific oral tolerance induction in children with cow's milk allergy: comparison with reported protocols. J Investig Allergol Clin Immunol. 2010;20:538–539. [PubMed] [Google Scholar]
  • 32.Nadeau K.C., Schneider L.C., Hoyte L., Borras I., Umetsu D.T. Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy. J Allergy Clin Immunol. 2011;127:1622–1624. doi: 10.1016/j.jaci.2011.04.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Pajno G.B., Caminiti L., Salzano G., et al. Comparison between two maintenance feeding regimens after successful cow's milk oral desensitization. Pediatr Allergy Immunol. 2013;24:376–381. doi: 10.1111/pai.12077. [DOI] [PubMed] [Google Scholar]
  • 34.Goldberg M.R., Nachshon L., Appel M.Y., et al. Efficacy of baked milk oral immunotherapy in baked milk-reactive allergic patients. J Allergy Clin Immunol. 2015;136:1601–1606. doi: 10.1016/j.jaci.2015.05.040. [DOI] [PubMed] [Google Scholar]
  • 35.Kim J.S., Nowak-Węgrzyn A., Sicherer S.H., Noone S., Moshier E.L., Sampson H.A. Dietary baked milk accelerates the resolution of cow's milk allergy in children. J Allergy Clin Immunol. 2011;128:125–131. doi: 10.1016/j.jaci.2011.04.036. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Dang T.D., Peters R.L., Allen K.J. Debates in allergy medicine: baked egg and milk do not accelerate tolerance to egg and milk. World Allergy Organ J. 2016;9:2. doi: 10.1186/s40413-015-0090-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Yeung J.P., Kloda L.A., McDevitt J., Ben-Shoshan M., Alizadehfar R. Oral immunotherapy for milk allergy. Cochrane Database Syst Rev. 2012;11:CD009542. doi: 10.1002/14651858.CD009542.pub2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Nurmatov U., Dhami S., Arasi S., et al. Allergen immunotherapy for IgE-mediated food allergy: a systematic review and meta-analysis. Allergy. 2017;72:1133–1147. doi: 10.1111/all.13124. [DOI] [PubMed] [Google Scholar]
  • 39.Koletzko S., Niggemann B., Arato A., et al. European Society of Pediatric Gastroenterology, Hepatology, and Nutrition. Diagnostic approach and management of cow's-milk protein allergy in infants and children: ESPGHAN GI Committee practical guidelines. J Pediatr Gastroenterol Nutr. 2012;55:221–229. doi: 10.1097/MPG.0b013e31825c9482. [DOI] [PubMed] [Google Scholar]
  • 40.Muraro A., Werfel T., Hoffmann-Sommergruber K., et al. EAACI food allergy and anaphylaxis guidelines: diagnosis and management of food allergy. Allergy. 2014;69:1008–1025. doi: 10.1111/all.12429. [DOI] [PubMed] [Google Scholar]
  • 41.Dupont C., Chouraqui J.P., de Boissieu D., et al. Comité de nutrition de la Société française de pédiatrie. Prise en charge diététique de l'allergie aux protéines du lait de vache [Dietetic treatment of cow's milk protein allergy] Arch Pediatr. 2011;18:79–94. doi: 10.1016/j.arcped.2010.08.029. [DOI] [PubMed] [Google Scholar]
  • 42.Caffarelli C., Baldi F., Bendandi B., Calzone L., Marani M., Pasquinelli P. Emilian Working Group on Pediatric Allergy and Gastroenterology. Cow's milk protein allergy in children: a practical guide. Ital J Pediatr. 2010;36:5. doi: 10.1186/1824-7288-36-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Fiocchi A., Brozek J., Schunemann H.J., et al. Organizzazione mondiale dell’allergia: le line-guida DRACMA (diagnosi e terapia della allergia alle proteine del latte vaccino) Rivista di Immunologia ed Allergologia Pediatrica. 2011;26(S1):1–104. [Google Scholar]
  • 44.Venter C., Brown T., Shah N., Walsh J., Fox A.T. Diagnosis and management of non-IgE-mediated cow's milk allergy in infancy – a UK primary care practical guide. Clin Transl Allergy. 2013;3:23. doi: 10.1186/2045-7022-3-23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Venter C., Brown T., Meyer R., et al. Better recognition, diagnosis and management of non-IgE-mediated cow's milk allergy in infancy: iMAP-an international interpretation of the MAP (Milk Allergy in Primary Care) guideline. Clin Transl Allergy. 2017;7:26. doi: 10.1186/s13601-017-0162-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Luyt D., Ball H., Makwana N., et al. British Society for Allergy and Clinical Immunology (BSACI) guideline for the diagnosis and management of cow's milk allergy. Clin Exp Allergy. 2014;44:642–672. doi: 10.1111/cea.12302. [DOI] [PubMed] [Google Scholar]
  • 47.Fox A., Brown T., Walsh J., et al. An update to the Milk Allergy in Primary Care guideline. Clin Transl Allergy. 2019;9:40. doi: 10.1186/s13601-019-0281-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Pelkonen A.S., Kuitunen M., Dunder T., Reijonen T., Valovirta E., Mäkelä M.J. Allergy in children: practical recommendations of the Finnish Allergy Programme 2008-2018 for prevention, diagnosis, and treatment. Pediatr Allergy Immunol. 2012;23:103–116. doi: 10.1111/j.1399-3038.2012.01298.x. [DOI] [PubMed] [Google Scholar]
  • 49.Martorell-Aragonés A., Echeverría-Zudaire L., Alonso-Lebrero E., et al. Food allergy committee of SEICAP (Spanish Society of Pediatric Allergy, Asthma and Clinical Immunology). Position document: IgE-mediated cow's milk allergy. Allergol Immunopathol (Madr). 2015;43:507–526. doi: 10.1016/j.aller.2015.01.003. [DOI] [PubMed] [Google Scholar]
  • 50.Espin Jaime B., Diaz Martin J.J., Blesa Baviera L.C., et al. Non-IgE-mediated cow's milk allergy: consensus document of the Spanish Society of Paediatric Gastroenterology, Hepatology, and Nutrition (SEGHNP), the Spanish Association of Paediatric Primary Care (AEPAP), the Spanish Society of Extra-hospital Paediatrics and Primary Health Care (SEPEAP), and the Spanish Society of Paediatric ClinicaL Immunology, Allergy, and Asthma (SEICAP) An Pediatr (Barc). 2019;90:1–193. doi: 10.1016/j.anpedi.2018.11.007. [DOI] [PubMed] [Google Scholar]
  • 51.Kansu A., Yüce A., Dalgıç B., Şekerel B.E., Çullu-Çokuğraş F., Çokuğraş H. Consensus statement on diagnosis, treatment and follow-up of cow's milk protein allergy among infants and children in Turkey. Turk J Pediatr. 2016;58:1–11. doi: 10.24953/turkjped.2016.01.001. [DOI] [PubMed] [Google Scholar]
  • 52.Vandenplas Y., Abuabat A., Al-Hammadi S., et al. Middle East consensus statement on the prevention, diagnosis, and management of cow's milk protein allergy. Pediatr Gastroenterol Hepatol Nutr. 2014;17:61–67. doi: 10.5223/pghn.2014.17.2.61. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Fiocchi A., Brozek J., Schunemann H.J., et al. World Allergy Organization The outline of World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) guidelines. Zhonghua Er Ke Za Zhi. 2012;50:510–515. [PubMed] [Google Scholar]
  • 54.Li H.Q. Intensive reading of World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) guideline. Zhonghua Er Ke Za Zhi. 2012;50:516–518. [PubMed] [Google Scholar]
  • 55.Ebisawa M., Ito K., Fujisawa T., Committee for Japanese Pediatric Guideline for Food Allergy, The Japanese Society of Pediatric Allergy and Clinical Immunology; Japanese Society of Allergology Japanese guidelines for food allergy 2020. Allergol Int. 2020;69:370–386. [Google Scholar]
  • 56.Montijo-Barrios E., López-Ugalde M.V., Ramírez-Mayans J., et al. Guía latinoamericana para el diagnóstico y tratamiento de alergia a las proteínas de la leche de vaca (GL-APLV) Rev Invest Clin. 2014;66(Suppl 2):S9–S72. [PubMed] [Google Scholar]
  • 57.Fiocchi A, Brozek J, Schunemann HJ, et al. Pautas de la Organización Mundial sobre Alergia para el Diagnóstico y Fundamento de la Acción Contra la Alergia a la Leche de Vaca. http://www.scp.com.co/ArchivosSCP/PDF/DRACMA.pdf, accessed May 5th, 2021.
  • 58.Wauters L., Brown T., Venter C., et al. Cow’s Milk Allergy Prescribing is influenced by Regional and National Guidance. J Pediatr Gastroenterol Nutr. 2016;62:688–693. doi: 10.1097/MPG.0000000000001052. [DOI] [PubMed] [Google Scholar]
  • 59.Fiocchi A., Fierro V., La Marra F. Interpreting the results of guideline implementation: a long and winding road. J Pediatr Gastroenterol Nutr. 2016;62:665–666. doi: 10.1097/MPG.0000000000001103. [DOI] [PubMed] [Google Scholar]
  • 60.Ruszczyński M., Horvath A., Dziechciarz P., Szajewska H. Cow's milk allergy guidelines: a quality appraisal with the AGREE II instrument. Clin Exp Allergy. 2016;46(9):1236-1241. doi: 10.1111/cea.12784. [DOI] [PubMed] [Google Scholar]
  • 61.Schünemann H.J., Lerda D., Dimitrova N., et al. European Commission Initiative on Breast Cancer Contributor Group Methods for development of the European Commission initiative on breast Cancer guidelines: recommendations in the era of guideline transparency. Ann Intern Med. 2019;171:273–280. doi: 10.7326/M18-3445. [DOI] [PubMed] [Google Scholar]
  • 62.Johansson S.G., Bieber T., Dahl R. Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, 2003. J Allergy Clin Immunol. 2004;113:832–836. doi: 10.1016/j.jaci.2003.12.591. [DOI] [PubMed] [Google Scholar]
  • 63.Anvari S., Miller J., Yeh C.Y., Davis C.M. IgE-mediated food allergy. Clin Rev Allergy Immunol. 2019;57:244–260. doi: 10.1007/s12016-018-8710-3. [DOI] [PubMed] [Google Scholar]
  • 64.Cardona V., Ansotegui I.J., Ebisawa M., et al. World allergy organization anaphylaxis guidance 2020. World Allergy Organ J. 2020;13:100472. doi: 10.1016/j.waojou.2020.100472. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Multimedia component 1
mmc1.docx (20.8KB, docx)

Articles from The World Allergy Organization Journal are provided here courtesy of World Allergy Organization

RESOURCES